Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
type: MedicalStudy
description: A Phase II Trial of Bevacizumab (NSC# 704865) and OSI-774 (NSC# 718781) In Recurrent Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma
status: COMPLETED
study design: INTERVENTIONAL
phase: PHASE2
start date: 2005-04
end date: 2010-04
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT00126542
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: National Cancer Institute (NCI)
study subject: Fallopian Tube Cancer
study subject: Primary Peritoneal Cavity Cancer
study subject: Recurrent Ovarian Epithelial Cancer
study subject: Stage IV Ovarian Epithelial Cancer
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: COMPLETED
keywords: Fallopian Tube Cancer
keywords: Primary Peritoneal Cavity Cancer
keywords: Recurrent Ovarian Epithelial Cancer
keywords: Stage IV Ovarian Epithelial Cancer

AI Analytics
type: Organization